Details about Adrian Towse

Access statistics for papers by Adrian Towse.

Last updated 2018-04-23. Update your information in the RePEc Author Service.

Short-id: pto443

Working Papers

2018

1. Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
   Consulting Reports, Office of Health Economics
2. Real World Evidence for Coverage Decisions: Opportunities and Challenges
   Research Papers, Office of Health Economics View citations (6)
3. Review of CRA's Report "Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe"
   Consulting Reports, Office of Health Economics
4. Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
   Research Papers, Office of Health Economics

2017

5. 'Macro' Evaluation of the NIHR Oxford Biomedical Research Centre
   Research Papers, Office of Health Economics
6. Additional Elements of Value for Health Technology Assessment Decisions
   Briefings, Office of Health Economics View citations (3)
7. Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
   Briefings, Office of Health Economics
8. Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
   Briefings, Office of Health Economics View citations (1)
9. Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
   Consulting Reports, Office of Health Economics View citations (3)
10. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
    Research Papers, Office of Health Economics View citations (2)
11. HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?
    Briefings, Office of Health Economics
12. How can HTA meet the needs of health system and government decision makers?
    Briefings, Office of Health Economics
13. Incentives for New Drugs to Tackle Anti-Microbial Resistance
    Briefings, Office of Health Economics View citations (2)
14. Policy Options for Formulary Development in Middle-income Countries
    Consulting Reports, Office of Health Economics View citations (1)
15. Transferability of HTA
    Briefings, Office of Health Economics View citations (1)

2016

16. Four Case Studies to Explore the Added Value of Oxford AHSN
    Consulting Reports, Office of Health Economics
17. How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
    Briefings, Office of Health Economics
18. Improving Efficiency and Resource Allocation in Future Cancer Care
    Consulting Reports, Office of Health Economics
19. Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
    Consulting Reports, Office of Health Economics View citations (1)
20. Uncertainty and Risk in HTA Decision Making
    Research Papers, Office of Health Economics View citations (3)

2015

21. Data Governance Arrangements for Real-World Evidence
    Consulting Reports, Office of Health Economics View citations (2)
22. International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa
    Occasional Papers, Office of Health Economics
23. Multi-indication Pricing: Pros, Cons and Applicability to the UK
    Seminar Briefings, Office of Health Economics View citations (7)

2014

24. Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
    Occasional Papers, Office of Health Economics
25. The Expanding Value Footprint of Oncology Treatments
    Consulting Reports, Office of Health Economics View citations (4)
26. What is the Role of HTA for Biosimilars?
    Briefings, Office of Health Economics View citations (2)

2013

27. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
    Occasional Papers, Office of Health Economics View citations (12)
28. Exploring the link between health and wealth in decision making
    Research Papers, Office of Health Economics

2012

29. Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
    Research Papers, Office of Health Economics View citations (4)
30. The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
    Occasional Papers, Office of Health Economics View citations (2)
31. Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)
    See also Journal Article in Health Economics (2015)

2011

32. Incentives for R&D for New Antimicrobial Drugs
    Research Papers, Office of Health Economics View citations (1)
    See also Journal Article in International Journal of the Economics of Business (2011)
33. Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
    Research Papers, Office of Health Economics View citations (1)
34. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
    See also Journal Article in Health Economics (2015)
35. Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
    Occasional Papers, Office of Health Economics View citations (2)
36. The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response
    Consulting Reports, Office of Health Economics View citations (6)

2010

37. New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
    Occasional Papers, Office of Health Economics View citations (1)
38. Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe
    Consulting Reports, Office of Health Economics View citations (1)
39. Using QALYs in Cancer: Review of the Methodological Limitations
    Research Papers, Office of Health Economics View citations (11)

2009

40. Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience
    Consulting Reports, Office of Health Economics

2008

41. The Market for Biosimilars: Evolution and Policy Options
    Briefings, Office of Health Economics View citations (8)

2006

42. Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
    Consulting Reports, Office of Health Economics
43. Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds
    Briefings, Office of Health Economics

2003

44. Reducing Harm to Patients in the National Health Service. Will the Government's Compensation Proposals Help?
    Briefings, Office of Health Economics View citations (1)

1998

45. From Efficacy to Cost-Effectiveness
    Briefings, Office of Health Economics View citations (3)

1997

46. Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
    Briefings, Office of Health Economics View citations (2)

Journal Articles

2017

1. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
   Health Policy, 2017, 121, (10), 1025-1030 View citations (5)

2016

2. Biosimilars: How Can Payers Get Long-Term Savings?
   PharmacoEconomics, 2016, 34, (6), 609-616 View citations (7)
3. Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
   Oxford Review of Economic Policy, 2016, 32, (1), 64-87

2015

4. European Union Pharmaceutical Markets: A Case for Differential Pricing?
   International Journal of the Economics of Business, 2015, 22, (2), 263-275 View citations (6)
5. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
   Health Economics, 2015, 24, (2), 238-252 View citations (10)
   See also Working Paper (2011)
6. Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context
   Health Economics, 2015, 24, (3), 294-301 View citations (12)
   See also Working Paper (2012)

2014

7. Orphan drugs policies: a suitable case for treatment
   The European Journal of Health Economics, 2014, 15, (4), 335-340 View citations (10)

2013

8. Operationalizing Value-Based Pricing of Medicines
   PharmacoEconomics, 2013, 31, (1), 1-10 View citations (13)

2012

9. Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
   The European Journal of Health Economics, 2012, 13, (1), 1-5 View citations (13)

2011

10. Incentives for R&D for New Antimicrobial Drugs
    International Journal of the Economics of Business, 2011, 18, (2), 331-350 View citations (1)
    See also Working Paper (2011)

2006

11. The desirability and feasibility of economic studies of drugs post-launch
    The European Journal of Health Economics, 2006, 7, (1), 5-6 View citations (1)

2004

12. Genetic screening, health care and the insurance industry
    The European Journal of Health Economics, 2004, 5, (2), 116-121 View citations (2)

1999

13. Is disease management relevant in Europe: some evidence from the United Kingdom
    Health Policy, 1999, 48, (1), 69-77
14. Medical negligence and the NHS: an economic analysis
    Health Economics, 1999, 8, (2), 93-101 View citations (6)

1994

15. The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8
    Health Economics, 1994, 3, (5), 347-348

Books

2012

1. The R&D Cost of a New Medicine
   Monographs, Office of Health Economics View citations (25)

2011

2. New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
   Monographs, Office of Health Economics View citations (4)

2010

3. Biosimilars: How Much Entry and Price Competition Will Result?
   Monographs, Office of Health Economics View citations (4)

2008

4. The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way
   Monographs, Office of Health Economics View citations (1)

2006

5. Economic Post-Launch Studies: Matching the Desirable with the Feasible
   Monographs, Office of Health Economics View citations (1)

2002

6. Cost-Effectiveness Thresholds: Economic and ethical issues
   Monographs, Office of Health Economics View citations (21)
7. Influencing Prescribing in a Primary Care Led NHS
   Monographs, Office of Health Economics
8. Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty
   Monographs, Office of Health Economics View citations (4)

1999

9. Disease Management, the NHS and the Pharmaceutical Industry
   Monographs, Office of Health Economics

1997

10. Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?
    Monographs, Office of Health Economics View citations (4)

1995

11. Financing Health Care in the UK: A Discussion of NERA's Prototype Model to Replace the NHS
    Monographs, Office of Health Economics View citations (2)
12. Industrial Policy and the Pharmaceutical Industry
    Monographs, Office of Health Economics View citations (2)
13. Value of the Pharmaceutical Industry to the UK Economy
    Monographs, Office of Health Economics View citations (1)